| Sep 23 |
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
|
| Sep 22 |
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
|
| Sep 14 |
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Aug 22 |
Looking Into Black Diamond Therapeutic's Recent Short Interest
|
| Aug 11 |
Wall Street Breakfast: The Week Ahead
|
| Aug 8 |
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
|
| Aug 8 |
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
|
| Aug 6 |
Black Diamond Therapeutics GAAP EPS of -$0.36 beats by $0.03
|
| Aug 6 |
Black Diamond: Q2 Earnings Snapshot
|
| Aug 6 |
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
